The BAX Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BAX gene in the human 143B osteosarcoma line. This heterogeneous pool of BAX-disrupted cells provides a loss-of-function model for studying pro-apoptotic signaling without clonal isolation. The polyclonal format reflects genetic heterogeneity, enabling the study of BAX-dependent phenotypes in a tumor-relevant context.
The 143B host cell line is a well-characterized human osteosarcoma line with epithelial morphology, derived from a primary bone tumor. Retaining osteoblastic features, 143B cells are widely used in bone tumor biology, osteosarcoma pathogenesis, and metastasis research. Their robust growth and facile genetic manipulation make them an ideal platform for CRISPR/Cas9-mediated gene disruption and functional assays.
BAX encodes a pro-apoptotic BCL-2 family protein that executes mitochondrial outer membrane permeabilization. Upon cellular stress, BAX undergoes conformational activation, translocates to mitochondria, and oligomerizes to form pores. This is regulated by upstream factors: p53 upregulates BAX transcription, while AKT phosphorylation promotes cytosolic retention. BH3-only proteins BIM and BAD activate BAX, opposing inhibition by BCL-2 and BCL-XL. At the membrane, BAX interacts with VDAC and Bak, facilitating cytochrome c release. Cytosolic cytochrome c binds APAF-1, assembling the apoptosome and sequentially activating caspase-9 and caspase-3 to execute apoptosis.
In osteosarcoma, apoptosis evasion is a hallmark contributing to therapeutic resistance. BAX deficiency or inactivation has been implicated in chemotherapeutic survival. The BAX Knockout 143B Polyclonal Cells serve as a loss-of-function model to dissect BAX contributions to intrinsic apoptosis in the bone cancer microenvironment. Comparing wild-type and BAX-disrupted cells allows delineation of mitochondrial apoptotic dependencies and identification of compensatory survival signals that arise upon BAX loss, yielding insights into drug resistance mechanisms.
This polyclonal knockout model supports diverse apoptosis studies, including dissection of BAX-dependent death mechanisms and chemoresistance in osteosarcoma. Researchers can confirm BAX ablation by Western blot, quantify apoptosis with Annexin V/PI flow cytometry, and assess mitochondrial integrity via cytochrome c release and membrane potential assays (JC-1). MTT viability and caspase activity assays further enable functional readouts. The polyclonal population captures heterogeneous responses, facilitating identification of BAX-independent survival pathways and evaluation of apoptosis-restoring agents. For inquiries, contact Ascent Research.
